Sizling Stocks Update: Ascena Retail Group, Inc. (NASDAQ:ASNA), ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

Ascena Retail Group, Inc. (NASDAQ:ASNA)

Citigroup Maintains Ascena Retail Group, Inc. (NASDAQ:ASNA)’s stock to Sell with the price target of $2. This rating was issued on 9/26/18. The stock recently closed its previous session at $3.68 by showing a percentage change of -2.39% from its previous day closing price of $3.77.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Ascena Retail Group, Inc. (NASDAQ:ASNA) in which B. Riley FBR Maintains Ascena Retail Group, Inc. (NASDAQ:ASNA) to Neutral by settling a price target of $4.5 on 8/15/18. B. Riley FBR Maintains the stock to Neutral on 3/06/18 by stationing a price target of $2. FBR Capital Maintains the company’s stock to Neutral on 8/15/17 by setting a price target of $3. KeyBanc Downgrades Ascena Retail Group, Inc. (NASDAQ:ASNA) to Sector Weight with no specific Price Target.

Ascena Retail Group, Inc. (NASDAQ:ASNA) currently has a consensus Price Target of $3.83. While some analysts have a High Price target for the stock of $5 and a Low Price Target of $2.

Several sell side analysts reviewed their recommendations on Ascena Retail Group, Inc. (NASDAQ:ASNA) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it’s a Buy, 4 rated the stock as Hold, 0 analysts reported Underperform and 1 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 3.67. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Ascena Retail Group, Inc. (NASDAQ:ASNA) reported its Actual EPS of $0.07/share. The analysts offering Earnings Estimates for the company were believing that Ascena Retail Group, Inc. (NASDAQ:ASNA) could bring EPS of $0.02/share. The difference between Actual EPS and Estimated EPS was 0.05 Percent. Thus the company showed an Earnings Surprise of 250 Percent.

Ascena Retail Group, Inc. (NASDAQ:ASNA) has a market capitalization of 707.29 Million. The stock traded with the volume of 1.74 Million shares in the last trading session. The stock touched its high share price of $5.28 on 08/22/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 02/06/18 as $1.79. The company has a 1 Year high price target of $3.83. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -11.33%. The Moving Average SMA50 is -15.31% while SMA200 is 13.74%.

Ascena Retail Group, Inc. (NASDAQ:ASNA) is currently showing its ROA (Return on Assets) of -1.1%. The Return on Investment (ROI) is at 1.1% while it’s Return on Equity (ROE) value stands at -5%. The stock currently shows its YTD (Year to Date) performance of 56.6 percent while its Weekly performance value is 1.38%. The Monthly and Yearly performances are -22.69 percent and 83.08 percent respectively. The Relative Volume value measured for Ascena Retail Group, Inc. (NASDAQ:ASNA) is 0.72. The Average Volume (3 months) is 2.42 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ASNA has P/E (Price to Earnings ttm) value of 0, Forward P/E of 75.1, P/C (Price to cash per share) of 3.08 and Price to Free Cash Flow (P/FCF) value of 8.45. The stock is showing its Operating Margin of 0.4 percent.

Company Profile:

Ascena Retail Group, Inc, formerly known as The Dress Barn, Inc., operates as a national specialty retailer of apparel for women and girls under the Dressbarn, Maurices and Justice brands. Its Dressbarn stores offer casual, career and special occasion fashion apparel and accessories; Maurices stores offer casual and career apparel and accessories; and Justice stores offer trend-right apparel and accessories. Ascena Retail Group, Inc. is based in Suffern, New York.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

JP Morgan Downgrades ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s stock to Underweight with no specific Price Target. This rating was issued on 6/18/18. The stock recently closed its previous session at $2.15 by showing a percentage change of 1.42% from its previous day closing price of $2.12.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) in which H.C. Wainwright Initiates Coverage On ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to Buy by settling a price target of $9.5 on 6/01/17. Wells Fargo Upgrades the stock to Market Perform on 8/10/16 with no specific Price Target. Raymond James Initiates Coverage on the company’s stock to Market Perform on 6/02/16 with no specific Price Target. Wells Fargo Initiates Coverage on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) to Underperform with no specific Price Target.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) currently has a consensus Price Target of $4.25. While some analysts have a High Price target for the stock of $5.5 and a Low Price Target of $3.

Several sell side analysts reviewed their recommendations on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) where 0 analyst have rated the stock as Strong Buy, 1 analysts said it’s a Buy, 2 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 3. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) reported its Actual EPS of $-0.12/share. The analysts offering Earnings Estimates for the company were believing that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) could bring EPS of $-0.12/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus the company showed an Earnings Surprise of 0 Percent.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has a market capitalization of 303.54 Million. The stock traded with the volume of 1.74 Million shares in the last trading session. The stock touched its high share price of $5.24 on 01/22/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/24/18 as $1.96. The company has a 1 Year high price target of $4.25. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -17.75%. The Moving Average SMA50 is -22.71% while SMA200 is -40.52%.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is currently showing its ROA (Return on Assets) of -77.2%. The Return on Investment (ROI) is at 55.3% while it’s Return on Equity (ROE) value stands at 67.9%. The stock currently shows its YTD (Year to Date) performance of -48.07 percent while its Weekly performance value is -3.15%. The Monthly and Yearly performances are -33.23 percent and -52.01 percent respectively. The Relative Volume value measured for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is 1.34. The Average Volume (3 months) is 1.3 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ZIOP has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 7.47 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.